SCHAUMBURG, Ill., June 3 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company with a focus on injectable products, today announced that president and chief executive officer, Jeffrey M. Yordon will present at the 8th Annual Needham Biotechnology & Medical Technology Conference at 2:30 p.m. on June 10, 2009.
The conference, which is taking place on June 10-11, 2009 at The New York Palace Hotel in New York, NY, will feature presentations by over 100 small and mid-cap biotechnology and life science companies along with a select group of private and large cap firms. In addition, several panel discussions will provide attendees with information from academic clinicians and researchers on disease breakthroughs and emerging technologies. The conference is open to clients of Needham & Company, LLC by invitation only.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.
To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.
CONTACT: investors, Ronald E. Pauli of Sagent, +1-847-908-1604; or media,
Aline Schimmel of WeissComm Partners, +1-312-646-6295, for Sagent
Pharmaceuticals, Inc.
